Oppenheimer Initiates Coverage On Pelthos Therapeutics with Outperform Rating, Announces Price Target of $50
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces Price Target of $50.
Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces Price Target of $50.
